Eli Lilly and Incyte have entered into an exclusive worldwide license and collaboration agreement for the development and commercialisation of Incyte’s oral JAK1/JAK2 inhibitor, INCB28050, and certain follow
Cpex Pharmaceuticals (Cpex) has completed enrollment in its ongoing phase 2a clinical trial of Nasulin, the company’s intranasal insulin candidate. Reportedly, the study was initiated in February of
Mettler Toledo, a manufacturer of precision instruments, has developed ‘Risk Check’, an online tool to analyze the weighing risk of balances from all kinds of manufacturers. Risk Check
Labopharm’s wholly-owned subsidiary, Labopharm Europe has completed a distribution and supply agreement with Merck Sharp & Dohme (MSD), a UK subsidiary of Merck & Co. As per the
Leo Pharma has reported positive results for the two phase III actinic (solar) keratosis (AK) clinical trials using PEP005 (ingenol mebutate) gel. It is meant for the treatment
Fibrocell Science has received a Complete Response letter from the FDA related to the Biologics License Application (BLA) for azficel-T, an autologous cell therapy for the treatment of
Australia-based CSL has announced that the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study H1N1 2009 ‘swine’
Actelion has reported the results of an arbitration proceeding in California between one of its subsidiaries, CoTherix, and Asahi Kasei Pharma (Japan), regarding a license agreement to develop
Astellas has submitted an application for market authorization for orally disintegrating tablet, YM905 (solifenacin succinate), to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. It has also
NicOx has submitted a marketing authorization application (MAA) for naproxcinod to the European Medicines Agency (EMEA), seeking approval for an indication for the relief of the signs and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.